Distribution of vesicular monoamine transporter 2 protein in human brain: Implications for brain imaging studies

Journal of Cerebral Blood Flow and Metabolism

Volumn 31, Issue 10, 2011, Pages 2065-2075

  Tong, Junchao ^a   Boileau, Isabelle ^a   Furukawa, Yoshiaki ^b   Chang, Li Jan ^a   Wilson, Alan A ^a   Houle, Sylvain ^a   Kish, Stephen J ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

Author keywords

cerebellum; occipital cortex; positron emission tomography; reference region; substantia nigra; vesicular monoamine transporter 2

Indexed keywords

DOPAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BASAL GANGLION; BRAIN CORTEX; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; GRAY MATTER; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MESENCEPHALON; NEOSTRIATUM; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; OCCIPITAL LOBE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PUTAMEN; SUBSTANTIA NIGRA;

AUTOPSY; BRAIN; HUMANS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 80053567505     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2011.63     Document Type: Article

References (44)

1. Aston JA, Cunningham VJ, Asselin MC, Hammers A, Evans AC, Gunn RN (2002) Positron emission tomography partial volume correction: estimation and algorithms. J Cereb Blood Flow Metab 22:1019-34 (Pubitemid 34831609)
2. Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J, Selby P, Wilson AA, Kish SJ (2010) Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans. Synapse 64:417-20
3. Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P, Guttman M, Saint-Cyr JA, Wilson AA, Kish SJ (2008) Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28:9850-6
4. Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ (2003) Assessment of neuroima-ging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184(Suppl 1):S68-79 (Pubitemid 37338706)
5. Chan GL, Holden JE, Stoessl AJ, Samii A, Doudet DJ, Dobko T, Morrison KS, Adam M, Schulzer M, Calne DB, Ruth TJ (1999) Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 40:283-9 (Pubitemid 29077091)
6. Cruz-Muros I, Afonso-Oramas D, Abreu P, Rodriguez M, Gonzalez MC, Gonzalez-Hernandez T (2008) Deglyco-sylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging. Neurobiol Aging 29:1702-11
7. Darchen F, Masuo Y, Vial M, Rostene W, Scherman D (1989) Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoke-tanserin. Neuroscience 33:341-9 (Pubitemid 20039717)
8. Duchemin AM, Zhang H, Neff NH, Hadjiconstantinou M (2009) Increased expression of VMAT2 in dopaminergic neurons during nicotine withdrawal. Neurosci Lett 467:182-6
9. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93:5166-71 (Pubitemid 26162890)
10. Fortune T, Lurie DI (2009) Chronic low-level lead exposure affects the monoaminergic system in the mouse superior olivary complex. J Comp Neurol 513:542-58
11. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE (1996) Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40:873-84 (Pubitemid 27044605)
12. Gainetdinov RR, Fumagalli F, Wang YM, Jones SR, Levey AI, Miller GW, Caron MG (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70:1973-8 (Pubitemid 28207819)
13. Gilman S, Frey KA, Koeppe RA, Junck L, Little R, Vander Borght TM, Lohman M, Martorello S, Lee LC, Jewett DM, Kilbourn MR (1996) Decreased striatal monoami-nergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Ann Neurol 40:885-92 (Pubitemid 27044606)
14. Gilman S, Koeppe RA, Adams KM, Junck L, Kluin KJ, Johnson-Greene D, Martorello S, Heumann M, Bandekar R (1998) Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C] dihydrotetrabenazine and positron emission tomography. Ann Neurol 44:326-33 (Pubitemid 28421436)
15. Gilman S, Koeppe RA, Junck L, Little R, Kluin KJ, Heumann M, Martorello S, Johanns J (1999) Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann Neurol 45:769-77 (Pubitemid 29260754)
16. Giovacchini G, Lerner A, Toczek MT, Fraser C, Ma K, DeMar JC, Herscovitch P, Eckelman WC, Rapoport SI, Carson RE (2004) Brain incorporation of 11C-arachido-nic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. J Nucl Med 45:1471-9 (Pubitemid 47618500)
17. Gonzalez-Hernandez T, Barroso-Chinea P, De La Cruz Muros I, Del Mar Perez-Delgado M, Rodriguez M (2004) Expression of dopamine and vesicular mono-amine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J Comp Neurol 479:198-215 (Pubitemid 39314891)
18. Gros Y, Schuldiner S (2010) Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter. J Biol Chem 285:5076-84
19. Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, Kish SJ (2003) Marked disparity between age-related changes in dopamine and other presynaptic dopami-nergic markers in human striatum. J Neurochem 87:574-85 (Pubitemid 37310624)
20. Henery CC, Mayhew TM (1989) The cerebrum and cerebellum of the fixed human brain: efficient and unbiased estimates of volumes and cortical surface areas. J Anat 167:167-80 (Pubitemid 20036031)
21. Holtje M, Winter S, Walther D, Pahner I, Hortnagl H, Ottersen OP, Bader M, Ahnert-Hilger G (2003) The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake. J Biol Chem 278:15850-8 (Pubitemid 36799700)
22. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51:S2-9 (Pubitemid 28397136)
23. Jassen AK, Brown JM, Panas HN, Miller GM, Xiao D, Madras BK (2005) Variants of the primate vesicular monoamine transporter-2. Brain Res Mol Brain Res 139:251-7 (Pubitemid 41317938)
24. Kilbourn MR, Butch ER, Desmond T, Sherman P, Harris PE, Frey KA (2010) In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol 37:3-8
25. Kilbourn MR, DaSilva JN, Frey KA, Koeppe RA, Kuhl DE (1993) In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography. J Neurochem 60:2315-8 (Pubitemid 23148808)
26. Kilbourn MR, Hockley B, Lee L, Hou C, Goswami R, Ponde DE, Kung MP, Kung HF (2007) Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol 34:233-7 (Pubitemid 46441862)
27. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, Houle S, Meyer JH (2005) Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 32:123-8 (Pubitemid 40260663)
28. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR (1999) Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 19:1376-84 (Pubitemid 30013629)
29. Little KY, Krolewski DM, Zhang L, Cassin BJ (2003) Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 160:47-55 (Pubitemid 36042426)
30. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 156:138-48 (Pubitemid 29152991)
31. Nirenberg MJ, Chan J, Liu Y, Edwards RH, Pickel VM (1996) Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 16:4135-45 (Pubitemid 26192409)
32. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O'Keefe G, Jones G, Kung HF, Pontecorvo MJ, Skovronsky D, Rowe CC (2010) In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 51:223-8
33. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH (1995) Differential expression of two vesicular monoamine transporters. J Neurosci 15:6179-88
34. Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE (2002) Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neurosci 22:8705-10 (Pubitemid 35387611)
35. Scherman D, Raisman R, Ploska A, Agid Y (1988) [3H]dihydrotetrabenazine, a new in vitro mono-aminergic probe for human brain. J Neurochem 50: 1131-6
36. Sievert MK, Ruoho AE (1997) Peptide mapping of the [125I] Iodoazidoketanserin and [125I] 2-N-[(30-iodo-40-azidophenyl) propionyl] tetrabenazine binding sites for the synaptic vesicle monoamine transporter. J Biol Chem 272:26049-55 (Pubitemid 27438935)
37. Tong J, Hornykiewicz O, Furukawa Y, Kish SJ (2007) Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens. J Neurochem 102:1691-702 (Pubitemid 47256195)
38. Tong J, Wilson AA, Boileau I, Houle S, Kish SJ (2008) Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 62:873-6
39. Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y (2010) Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 133:172-88
40. Troiano AR, Schulzer M, de la Fuente-Fernandez R, Mak E, McKenzie J, Sossi V, McCormick S, Ruth TJ, Stoessl AJ (2010) Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse 64:146-51
41. Vander Borght TM, Sima AA, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA (1995) [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoami-nergic neuronal integrity. Neuroscience 68:955-62
42. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19:1285-96 (Pubitemid 28030547)
43. Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K, Niznik HB, Hornykiewicz O, Pifl C, Kish SJ (1996) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47:718-26 (Pubitemid 26307303)
44. Yelin R, Steiner-Mordoch S, Aroeti B, Schuldiner S (1998) Glycosylation of a vesicular monoamine transporter: a mutation in a conserved proline residue affects the activity, glycosylation, and localization of the transporter. J Neurochem 71:2518-27 (Pubitemid 28531263)